Over the past few months, we’ve been excited to welcome several new faces to the FULcrew. To all our new teammates - welcome! We’re thrilled to have you.
Fulcrum Therapeutics
Biotechnology Research
Cambridge, Massachusetts 13,517 followers
About us
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases. Community Guidelines: https://bit.ly/3t2xeR9
- Website
-
http://www.fulcrumtx.com
External link for Fulcrum Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cambridge, Massachusetts
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Gene Regulation, Neuromuscular Diseases, Rare Genetic Diseases, and Cardiovascular Diseases
Locations
-
Primary
Get directions
26 Landsdowne St
Cambridge, Massachusetts 02139, US
Employees at Fulcrum Therapeutics
Updates
-
From patient to future physician, Hanif Mouehla’s journey shows what hope and healing can look like for the sickle cell community. #SickleCellAwareness #HarvardPreMed #StoriesOfStrength
-
Gathering for our All Hands just before Thanksgiving came with a meaningful reminder: none of this work happens alone. We’re grateful for our team and for the rare disease community who continue to inspire, challenge, and partner with us. Thank you for being part of this mission with us. Wishing you and your loved ones a warm and restful Thanksgiving! #HappyThanksgiving #Biotech #RareDisease
-
-
Risk vs. Reward in Biotech. For Fulcrum, the decision is clear: patients make the potential rewards greater than any risk. Hear from our own Sara Johnson Davis, VP, Head of Patient Advocacy & Policy, in her latest interview with the Milken Institute's Executive Insights series! #ScienceForPatients #Leadership
Milken Institute Health focuses on advancing a whole-person health approach. The Executive Insights series is a thought leadership component of the broader Employer Action Exchange platform that features brief and meaningful insights captured through interviews with executives from a variety of industries and sectors. We hope this series will spark ideas and inspire more leaders to take steps toward implementing #wholepersonhealth for their workforces. Click here for Sabrina Spitaletta Johar's interview with Sara Johnson Davis, vice president, head of patient advocacy & policy, Fulcrum Therapeutics.
-
Empowerment. Strength. Courage. Those three words were more than a theme at SCDAA’s 53rd Annual Convention. They were the energy in every session, every conversation, and every moment. Thank you to SCDAA for bringing the community together for this year’s convention, and to all the speakers who inspired us to keep forging ahead with strength and courage. Sickle Cell Disease Association of America, Inc. — National, Cayenne Wellness Center & Children´s Foundation, Sickle Cell Reproductive Health Education Directive, André Marcel Harris, MSW #SCDAA #Empowerment
-
Fulcrum Therapeutics is proud to join over 60 rare disease companies urging the immediate restoration of the Rare Pediatric Disease Priority Review Voucher (PRV) Program. This program is a crucial, cost-effective tool that stimulates research and development (R&D) for therapies aimed at rare, often fatal, pediatric diseases. The PRV incentive is vital for attracting investment into the rare disease space, mitigating risk, and ensuring innovators can deliver first-in-class treatments where they are desperately needed. Our CEO, Alex Sapir, signed the joint CEO letter calling for Congress to act swiftly to reauthorize the program. The future of hope for children with rare diseases depends on its restoration. #RareDisease #PediatricHealth #DrugDevelopment #Innovation
The rare disease innovator community is united in our support for the Rare Pediatric Disease Priority Review Voucher (PRV) Program. This week, the Rare Disease Company Coalition and the Alliance for Regenerative Medicine (ARM) led a joint letter to Congress urging the swift reauthorization of the PRV program. The letter is signed by over 60 biopharmaceutical CEOs at the forefront of rare disease innovation. To date, the PRV program has spurred the development of therapies across 47 indications and benefited more than 200,00 patients. Beyond serving as a crucial source of hope for children and their families, this program drives innovation, standing as a critical resource for companies developing treatments for rare disease patients. Together with ARM and dozens of leaders from across the rare disease ecosystem, we’re eager to work with Congress to reauthorize this vital program and ensure continued hope for children living with rare diseases. Read our letter: https://lnkd.in/ebdXtczT #RareDisease #OneRareVoice
-
We’re thrilled to welcome Lisa Percival as our new Chief Regulatory Officer! With decades of global regulatory experience and a career dedicated to the development of new medicines for high unmet need diseases and expanding access for patients, Lisa brings exceptional leadership and expertise to the FULcrew. Welcome to the team, Lisa! #FULcrew #Leadership #Biotech #RareDisease
-
-
Today we honor those who’ve served. At Fulcrum, we also recognize that service can come with unseen challenges, including health risks linked to genetic traits like Sickle Cell Trait (SCT). Service members with SCT face a 24% higher risk of complications during intense physical exertion. It’s a reminder of why lifelong, equitable healthcare for veterans matters and why awareness is key to protecting those who protect us. Thank you to all who have served. Source: Risk of Exertional Heat Illnesses Associated with Sickle Cell Trait in U.S. Military (2019) #VeteransDay #SickleCellAwareness
-
-
This September, we honored Sickle Cell Awareness Month. It was a time to listen, learn, and take action alongside the people living this story every day. Over the month, we had the chance to make fresh connections and reconnect in so many meaningful ways. From the Cayenne Wellness Summit to our Sickle Cell Warrior Panel, from community partnerships and walks in Houston and Michigan to our first global patient webinar, we were reminded that awareness is just the beginning. Each moment and each person reminded us that what matters most are the connections that last long after September ends. #SickleCellAwarenessMonth #SickleCellDisease #SickleCellCommunity
-
Happy Halloween! The FULcrew went all in on this year’s theme: “Dress like your job…but make it exaggerated!” #DressLikeYourJob #CostumeChallenge